Cargando…

Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma

Systemic treatment for advanced hepatocellular carcinoma (HCC) has been revolutionized over the last few years following the approval of immune checkpoint inhibitors (ICI). Despite the promising survival extension seen with ICI combination regimens, responses are not universally seen and the optimal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Manfredi, Giulia Francesca, Celsa, Ciro, John, Chloe, Jones, Charlotte, Acuti, Nicole, Scheiner, Bernhard, Fulgenzi, Claudia Angela Maria, Korolewicz, James, Pinter, Matthias, Gennari, Alessandra, Mauri, Francesco A, Pirisi, Mario, Minisini, Rosalba, Vincenzi, Federica, Burlone, Michela, Rigamonti, Cristina, Donadon, Matteo, Cabibbo, Giuseppe, D’Alessio, Antonio, Pinato, David James
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629523/ https://www.ncbi.nlm.nih.gov/pubmed/37941812 http://dx.doi.org/10.2147/JHC.S291553

Ejemplares similares

17β-Oestradiol Protects from Hepatitis C Virus Infection through Induction of Type I Interferon
por: Barbaglia, Matteo Nazzareno, et al.
Publicado: (2022)

Liver Stiffness, Not Fat Liver Content, Predicts the Length of QTc Interval in Patients with Chronic Liver Disease
por: Bellan, Mattia, et al.
Publicado: (2019)

Cardiac dysfunction as an early predictor of portal hypertension in chronic hepatitis C
por: Marconi, Cecilia, et al.
Publicado: (2017)

Direct antivirals and cognitive impairment in hepatitis C: a clinical-neurophysiologic study
por: Vaghi, Gloria, et al.
Publicado: (2020)

Periostin Circulating Levels and Genetic Variants in Patients with Non-Alcoholic Fatty Liver Disease
por: Smirne, Carlo, et al.
Publicado: (2020)

Improvement of insulin sensitivity in diabetic and non diabetic patients with chronic hepatitis C treated with direct antiviral agents
por: Gualerzi, Alessandro, et al.
Publicado: (2018)

17,β‐estradiol inhibits hepatitis C virus mainly by interference with the release phase of its life cycle
por: Magri, Andrea, et al.
Publicado: (2016)

Immunotherapy in Hepatocellular Carcinoma
por: Fulgenzi, Claudia A. M., et al.
Publicado: (2021)

Phenotypic Characteristics of the Tumour Microenvironment in Primary and Secondary Hepatocellular Carcinoma
por: Fessas, Petros, et al.
Publicado: (2021)

Interplay of PNPLA3 and HSD17B13 Variants in Modulating the Risk of Hepatocellular Carcinoma among Hepatitis C Patients
por: De Benedittis, Carla, et al.
Publicado: (2020)

Exposure to Plasma From Non-alcoholic Fatty Liver Disease Patients Affects Hepatocyte Viability, Generates Mitochondrial Dysfunction, and Modulates Pathways Involved in Fat Accumulation and Inflammation
por: Grossini, Elena, et al.
Publicado: (2021)

Immunotherapy for the treatment of hepatocellular carcinoma: finally in clinical practice
por: Celsa, Ciro, et al.
Publicado: (2023)

Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma
por: Pinato, David J., et al.
Publicado: (2023)

Role of Gas6 and TAM Receptors in the Identification of Cardiopulmonary Involvement in Systemic Sclerosis and Scleroderma Spectrum Disorders
por: Bellan, Mattia, et al.
Publicado: (2020)

Clinical Relevance of Liver Involvement in the Clinical Course of Systemic Sclerosis
por: Lorena, Maria, et al.
Publicado: (2022)

PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects
por: D’Alessio, Antonio, et al.
Publicado: (2021)

Pancreatobiliary Reflux Resulting in Pancreatic Ascites and Choleperitoneum after Gallbladder Perforation
por: Rapetti, Rachele, et al.
Publicado: (2008)

Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib
por: Howell, Jessica A., et al.
Publicado: (2017)

Finding the seed of recurrence: Hepatocellular carcinoma circulating tumor cells and their potential to drive the surgical treatment
por: Carissimi, Francesca, et al.
Publicado: (2021)

Identification of the Best Cut-Off Value of PIVKA-II for the Surveillance of Patients at Risk of Hepatocellular Carcinoma Development
por: Caviglia, Gian Paolo, et al.
Publicado: (2023)

The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma
por: Muhammed, Ambreen, et al.
Publicado: (2021)

Identification of a Functional, CRM-1-Dependent Nuclear Export Signal in Hepatitis C Virus Core Protein
por: Cerutti, Andrea, et al.
Publicado: (2011)

Understanding protection from SARS-CoV-2 using metabolomics
por: Barberis, Elettra, et al.
Publicado: (2021)

Ivabradine for inappropriate sinus tachycardia-induced symptomatic Mobitz type I atrio-ventricular block: a case summary
por: Korolewicz, James, et al.
Publicado: (2023)

Determinants of long COVID among adults hospitalized for SARS-CoV-2 infection: A prospective cohort study
por: Bellan, Mattia, et al.
Publicado: (2022)

NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy
por: Pinter, Matthias, et al.
Publicado: (2023)

Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups
por: Pinter, Matthias, et al.
Publicado: (2021)

Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma
por: Cabibbo, Giuseppe, et al.
Publicado: (2020)

Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study
por: Joerg, Vincent, et al.
Publicado: (2023)

ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma
por: Demirtas, Coskun O., et al.
Publicado: (2021)

Immunotherapy in hepatocellular carcinoma: how will it reshape treatment sequencing?
por: Cammarota, Antonella, et al.
Publicado: (2023)

Gas6/TAM Signaling Components as Novel Biomarkers of Liver Fibrosis
por: Smirne, Carlo, et al.
Publicado: (2019)

Histopathological and Immune Prognostic Factors in Colo-Rectal Liver Metastases
por: Rigamonti, Alessandra, et al.
Publicado: (2021)

The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints
por: Giuffrida, Paolo, et al.
Publicado: (2022)

Increased Levels of ICOS and ICOSL Are Associated to Pulmonary Arterial Hypertension in Patients Affected by Connective Tissue Diseases
por: Bellan, Mattia, et al.
Publicado: (2022)

Levosimendan Inhibits Peroxidation in Hepatocytes by Modulating Apoptosis/Autophagy Interplay
por: Grossini, Elena, et al.
Publicado: (2015)

Red Cell Distribution Width and Platelet Count as Biomarkers of Pulmonary Arterial Hypertension in Patients with Connective Tissue Disorders
por: Bellan, Mattia, et al.
Publicado: (2019)

COVID-19 Biomarkers at the Crossroad between Patient Stratification and Targeted Therapy: The Role of Validated and Proposed Parameters
por: Rizzi, Manuela, et al.
Publicado: (2023)

Plasma Pattern of Extracellular Vesicles Isolated from Hepatitis C Virus Patients and Their Effects on Human Vascular Endothelial Cells
por: Grossini, Elena, et al.
Publicado: (2023)

Decreased Gas6 and sAxl Plasma Levels Are Associated with Hair Loss in COVID-19 Survivors
por: Apostolo, Daria, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_boggeak9s8314rj4s5e8j4iqqm